Literature DB >> 9852193

Autoimmune diseases as stem cell disorders: normal stem cell transplant for their treatment (Review).

S Ikehara1.   

Abstract

Using various animal models for autoimmune diseases, we have found that autoimmune diseases are stem cell disorders. The transplantation of normal hemopoietic stem cells (HSCs) can be used to treat autoimmune diseases, whereas the transplantation of abnormal HSCs from autoimmune-prone mice to normal mice leads to the induction of autoimmune diseases in recipients. To elucidate the differences between normal and abnormal HSCs, we have established a new method for purifying pluripotent-HSCs (P-HSCs), and have compared the qualitative differences. Although normal P-HSCs cannot proliferate under major histocompatibility complex (MHC)-incompatible microenvironments (stromal cells), abnormal P-HSCs can proliferate under such conditions. In addition, the proliferation of abnormal P-HSCs is much faster than that of normal P-HSCs. These findings indicate that abnormal P-HSCs are more resilient than normal P-HSCs. Therefore, we propose that allogeneic bone marrow transplantation (BMT) (not autologous BMT) should be applied to the treatment of autoimmune diseases. human data on BMT in autoimmune diseases is reviewed, and the conditions essential for successful BMT, including tolerance induction, are discussed.

Entities:  

Mesh:

Year:  1998        PMID: 9852193     DOI: 10.3892/ijmm.1.1.5

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

Review 1.  Prospects of stem cell transplantation in autoimmune diseases.

Authors:  R A Nash
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

Review 2.  Epoxyeicosatrienoic acids and heme oxygenase-1 interaction attenuates diabetes and metabolic syndrome complications.

Authors:  Angela Burgess; Luca Vanella; Lars Bellner; Michal L Schwartzman; Nader G Abraham
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-11-15       Impact factor: 3.072

3.  Innovative BMT methods for intractable diseases.

Authors:  Susumu Ikehara
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 4.  New allogeneic hematopoietic stem cell transplantation method: hematopoietic stem cell transplantation plus thymus transplantation for intractable diseases.

Authors:  Naoki Hosaka
Journal:  Clin Dev Immunol       Date:  2013-05-12

5.  Association of TNF-α with impaired migration capacity of mesenchymal stem cells in patients with systemic lupus erythematosus.

Authors:  Linyu Geng; Xia Li; Xuebing Feng; Jiyun Zhang; Dandan Wang; Jinyun Chen; Rui Liu; Haifeng Chen; Lingyun Sun
Journal:  J Immunol Res       Date:  2014-11-24       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.